In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
Base editing
CRISPR-Cas9
Genome editing
Hypercholesterolemia
PCSK9
Journal
BMC biology
ISSN: 1741-7007
Titre abrégé: BMC Biol
Pays: England
ID NLM: 101190720
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
22
10
2018
accepted:
28
12
2018
entrez:
17
1
2019
pubmed:
17
1
2019
medline:
10
7
2019
Statut:
epublish
Résumé
Plasma concentration of low-density lipoprotein (LDL) cholesterol is a well-established risk factor for cardiovascular disease. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates cholesterol homeostasis, has recently emerged as an approach to reduce cholesterol levels. The development of humanized animal models is an important step to validate and study human drug targets, and use of genome and base editing has been proposed as a mean to target disease alleles. To address the lack of validated models to test the safety and efficacy of techniques to target human PCSK9, we generated a liver-specific human PCSK9 knock-in mouse model (hPCSK9-KI). We showed that plasma concentrations of total cholesterol were higher in hPCSK9-KI than in wildtype mice and increased with age. Treatment with evolocumab, a monoclonal antibody that targets human PCSK9, reduced cholesterol levels in hPCSK9-KI but not in wildtype mice, showing that the hypercholesterolemic phenotype was driven by overexpression of human PCSK9. CRISPR-Cas9-mediated genome editing of human PCSK9 reduced plasma levels of human and not mouse PCSK9, and in parallel reduced plasma concentrations of total cholesterol; genome editing of mouse Pcsk9 did not reduce cholesterol levels. Base editing using a guide RNA that targeted human and mouse PCSK9 reduced plasma levels of human and mouse PCSK9 and total cholesterol. In our mouse model, base editing was more precise than genome editing, and no off-target editing nor chromosomal translocations were identified. Here, we describe a humanized mouse model with liver-specific expression of human PCSK9 and a human-like hypercholesterolemia phenotype, and demonstrate that this mouse can be used to evaluate antibody and gene editing-based (genome and base editing) therapies to modulate the expression of human PCSK9 and reduce cholesterol levels. We predict that this mouse model will be used in the future to understand the efficacy and safety of novel therapeutic approaches for hypercholesterolemia.
Sections du résumé
BACKGROUND
Plasma concentration of low-density lipoprotein (LDL) cholesterol is a well-established risk factor for cardiovascular disease. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates cholesterol homeostasis, has recently emerged as an approach to reduce cholesterol levels. The development of humanized animal models is an important step to validate and study human drug targets, and use of genome and base editing has been proposed as a mean to target disease alleles.
RESULTS
To address the lack of validated models to test the safety and efficacy of techniques to target human PCSK9, we generated a liver-specific human PCSK9 knock-in mouse model (hPCSK9-KI). We showed that plasma concentrations of total cholesterol were higher in hPCSK9-KI than in wildtype mice and increased with age. Treatment with evolocumab, a monoclonal antibody that targets human PCSK9, reduced cholesterol levels in hPCSK9-KI but not in wildtype mice, showing that the hypercholesterolemic phenotype was driven by overexpression of human PCSK9. CRISPR-Cas9-mediated genome editing of human PCSK9 reduced plasma levels of human and not mouse PCSK9, and in parallel reduced plasma concentrations of total cholesterol; genome editing of mouse Pcsk9 did not reduce cholesterol levels. Base editing using a guide RNA that targeted human and mouse PCSK9 reduced plasma levels of human and mouse PCSK9 and total cholesterol. In our mouse model, base editing was more precise than genome editing, and no off-target editing nor chromosomal translocations were identified.
CONCLUSIONS
Here, we describe a humanized mouse model with liver-specific expression of human PCSK9 and a human-like hypercholesterolemia phenotype, and demonstrate that this mouse can be used to evaluate antibody and gene editing-based (genome and base editing) therapies to modulate the expression of human PCSK9 and reduce cholesterol levels. We predict that this mouse model will be used in the future to understand the efficacy and safety of novel therapeutic approaches for hypercholesterolemia.
Identifiants
pubmed: 30646909
doi: 10.1186/s12915-018-0624-2
pii: 10.1186/s12915-018-0624-2
pmc: PMC6334452
doi:
Substances chimiques
Cholesterol
97C5T2UQ7J
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Références
Circ Res. 2014 Aug 15;115(5):488-92
pubmed: 24916110
Swiss Med Wkly. 2015 Apr 09;145:w14094
pubmed: 25856746
J Biol Chem. 1991 Aug 25;266(24):15559-62
pubmed: 1651914
Nat Genet. 2003 Jun;34(2):154-6
pubmed: 12730697
Ann Intern Med. 2015 Jul 7;163(1):40-51
pubmed: 25915661
Nature. 2016 Apr 20;533(7603):420-4
pubmed: 27096365
Nat Med. 2018 Oct;24(10):1513-1518
pubmed: 30297903
Nat Biotechnol. 2017 May;35(5):475-480
pubmed: 28398345
Circ J. 2016;80(2):512-8
pubmed: 26632531
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45
pubmed: 21487090
Am J Hum Genet. 2006 Sep;79(3):514-23
pubmed: 16909389
Atherosclerosis. 2012 Aug;223(2):394-400
pubmed: 22683120
Mol Ther. 2018 Nov 7;26(11):2631-2637
pubmed: 30166242
Curr Opin Lipidol. 2007 Jun;18(3):304-9
pubmed: 17495605
Nature. 2015 Apr 9;520(7546):186-91
pubmed: 25830891
Clin Investig Arterioscler. 2016 May;28 Suppl 2:22-30
pubmed: 27888902
Nat Genet. 2005 Feb;37(2):161-5
pubmed: 15654334
N Engl J Med. 2015 Apr 16;372(16):1500-9
pubmed: 25773607
Circ Cardiovasc Genet. 2015 Dec;8(6):823-31
pubmed: 26374825
Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1741-1747
pubmed: 28751571
J Clin Lipidol. 2017 Nov - Dec;11(6):1485-1487
pubmed: 29056268
Sci Adv. 2017 Aug 30;3(8):eaao4774
pubmed: 28875174
Anatol J Cardiol. 2017 Oct;18(4):266-272
pubmed: 28777095
Nat Biotechnol. 2015 Feb;33(2):187-197
pubmed: 25513782
J Lipid Res. 2014 Nov;55(11):2370-9
pubmed: 25258384
Arterioscler Thromb Vasc Biol. 2016 May;36(5):783-6
pubmed: 26941020
Nat Biotechnol. 2018 Oct;36(9):888-893
pubmed: 29969439
Trends Biochem Sci. 2007 Feb;32(2):71-7
pubmed: 17215125
Atheroscler Suppl. 2017 Nov;30:33-37
pubmed: 29096858
Nat Biotechnol. 2018 Sep;36(8):765-771
pubmed: 30010673
Genes Dev. 1987 May;1(3):268-76
pubmed: 3678824
Nat Biotechnol. 2018 Oct;36(9):843-846
pubmed: 29813047
N Engl J Med. 2015 Apr 16;372(16):1489-99
pubmed: 25773378
J Clin Lipidol. 2014 Nov-Dec;8(6):554-61
pubmed: 25499937
Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9820-5
pubmed: 19443683
Mol Cell. 2014 Sep 18;55(6):829-842
pubmed: 25201414
J Am Coll Cardiol. 2015 Nov 10;66(19):2152-2154
pubmed: 26541928
J Physiol Pharmacol. 2008 Aug;59 Suppl 2:251-62
pubmed: 18812643
J Am Coll Cardiol. 2014 Jun 17;63(23):2541-2548
pubmed: 24694531
Nature. 2017 Nov 23;551(7681):464-471
pubmed: 29160308
N Engl J Med. 2017 May 4;376(18):e38
pubmed: 28467871
Curr Cardiol Rep. 2015 May;17(5):27
pubmed: 25894795
Lancet. 2014 Jan 4;383(9911):60-68
pubmed: 24094767
Atherosclerosis. 2009 Jun;204(2):e52-7
pubmed: 19091316
Nat Biotechnol. 2017 May;35(5):435-437
pubmed: 28244995
Science. 2016 Sep 16;353(6305):
pubmed: 27492474
Expert Opin Ther Targets. 2011 Feb;15(2):157-68
pubmed: 21204732
Lancet. 2015 Jan 24;385(9965):341-50
pubmed: 25282520
Nat Rev Cancer. 2007 Apr;7(4):233-45
pubmed: 17361217
J Clin Lipidol. 2015 Nov-Dec;9(6):758-769
pubmed: 26687696
JAMA. 2012 Mar 28;307(12):1302-9
pubmed: 22453571
Atherosclerosis. 2014 Sep;236(1):54-61
pubmed: 25014035
Nature. 2018 Sep;561(7723):416-419
pubmed: 30209390